Home › B-Cell Lymphoma › Connecticut › New Haven
B-Cell Lymphoma clinical trials in New Haven, CT
6 studies for B-Cell Lymphoma are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Yale University Yale Cancer Center, New Haven
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- Yale University School of Medicine - Yale Cancer Center, New Haven
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
- Yale University, New Haven
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RecruitingPhase 1
- Clinical Trial Site, New Haven
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RecruitingPhase 2
- Yale Cancer Center, New Haven
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Yale University, New Haven
B-Cell Lymphoma trials in other cities
- New York City, NY19 studies
- Houston, TX16 studies
- Chicago, IL12 studies
- Nashville, TN11 studies
- Philadelphia, PA11 studies
- Rochester, MN10 studies
- Baldwin Park, CA9 studies
- Milwaukee, WI9 studies
- Cleveland, OH8 studies
- Boston, MA8 studies
- Washington, DC7 studies
- Denver, CO7 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)34 studies
- Metastatic Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Colorectal Cancer21 studies
- Prostate Cancer21 studies
- Ovarian Cancer21 studies
- Acute Myeloid Leukemia19 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.